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Abstract
Tumor growth and metastasis depend on angiogen-
esis; therefore, efforts are made to develop specific
angiogenic inhibitors. Halofuginone (HF) is a potent
inhibitor of collagen type A1(I). In solid tumor models,
HF has a potent antitumor and antiangiogenic effect
in vivo, but its effect on brain tumors has not yet been
evaluated. By employing magnetic resonance imaging
(MRI), we monitored the effect of HF on tumor pro-
gression and vascularization by utilizing an implanted
malignant fibrous histiocytoma metastatic rat brain
tumor model. Here we demonstrate that treatment
with HF effectively and dose-dependently reduced
tumor growth and angiogenesis. On day 13, HF-treated
tumors were fivefold smaller than control (P < .001).
Treatment with HF significantly prolonged survival of
treated animals (142%; P = .001). In HF-treated rats,
tumor vascularization was inhibited by 30% on day
13 and by 37% on day 19 (P < .05). Additionally, HF
treatment inhibited vessel maturation (P = .03). Finally,
in HF-treated rats, we noticed the appearance of a few
clusters of satellite tumors, which were distinct from
the primary tumor and usually contained vessel cores.
This phenomenon was relatively moderate when com-
pared to previous reports of other antiangiogenic
agents used to treat brain tumors. We therefore con-
clude that HF is effective for treatment of metastatic
brain tumors.
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Introduction
Patients with malignant primary and metastatic brain
tumors have poor prognosis, despite developments in diag-
nostic and therapeutic modalities. Conventional therapy is
seldom curative and, therefore, a search for new thera-
peutic avenues is ongoing. The inhibition of angiogenesis—
the sprouting of new capillaries from pre-existing vascula-
ture—seems to offer a promising approach to tumor growth
arrest [1,2]. Its relevance is derived from the observation
that most tumors and metastases originate as small avascular
masses that later induce the development of new blood ves-
sels once they grow beyond a few millimeters in size [3].
Furthermore, high-grade brain tumors are characterized by
endothelial proliferation and a high degree of vascularity. In
these tumors, the amount of neovasculature is closely corre-
lated with the degree of malignancy and the prognosis of the
patient [4–6].
Collagen type I, a major component of the extracellular
matrix (ECM), plays an important role in the proliferation and
invasion of endothelial cells (ECs) [7]. A marked increase in
the transcription of type I collagen was demonstrated in ECs
undergoing angiogenesis [8] and blockage of collagen secre-
tion inhibited EC migration [9]. Experimentally, capillary ECs
reorganize into a network of branching and anastomosing
capillary-like tubes when sandwiched between two layers of
type I collagen gel [10]. When the collagen type I fibrils make
contact with the apical side of the endothelium, they act as a
stimulus to provide a template for vascular tube formation [11].
The receptors for the native collagen, the a1b1 and a2b1 integ-
rins, are highly expressed by ECs during angiogenesis. Anti-
bodies that block these receptors selectively inhibit vascular
endothelial growth factor (VEGF)-driven angiogenesis without
affecting pre-existing vasculature [12]. Halofuginone (HF), a
low-molecular-weight (MW = 495) quinazolinone alkaloid, is
a potent inhibitor of collagen type a1(I) synthesis at the tran-
scriptional level [13,14]. In culture, HF has been found to
attenuate collagen a1(I) gene expression and collagen pro-
duction. It inhibits vascular tube formation and, accordingly,
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was found to be an inhibitor of both angiogenesis and tumor
growth in in vitro models. In vivo, it has potent antitumor
and antimetastatic effects in systemic solid tumor models
[15–17].
In the past, several antiangiogenic agents have shown
an inhibitory effect in numerous experimental models
[16,18–20]. However, when evaluating antiangiogenic strat-
egies in animal models, one must consider that the morphol-
ogy and function of the tumor vasculature are largely
dependent upon the host environment. As some primary
central nervous system (CNS) tumors often show a highly
infiltrative growth pattern, it raises the question of whether
the vessels in such tumors are formed by angiogenesis or
are pre-existent ones. Indeed, the use of pre-existent ves-
sels in early metastatic outgrowths in the brain, a process
referred to as vessel cooption, has been reported [21,22]. As
these tumors progress, they switch to an angiogenic pheno-
type and new vessels penetrate from the surrounding vas-
culature. In this regard, it is important to realize that most
antiangiogenic studies have been carried out in animal
models where tumors were grown subcutaneously. Espe-
cially for CNS tumor biology, subcutaneous models have
limited clinical relevance since the subcutaneous space is
essentially avascular. Thus, the subcutaneous tumors are
artificially selected to grow in an angiogenic-dependent
fashion, whereas the microenvironmental conditions that
exist in the brain are of a highly vascularized nature.
There are few models for studying brain metastasis. The
model of internal carotid artery injection of tumor cells is one
of the suitable biologic models for metastatic dissemination
[22]. However, with such a model, the locations and sizes
of the lesions are heterogeneous and unpredictable. Thus,
for the study of antitumor effect of a new drug, the use of
a model with a precisely known location, size, and growth
kinetics is of great advantage. We chose to work with a well-
characterized model that uses cells of malignant fibrous
histiocytoma, which are injected into the right cerebral hemi-
sphere [23,24]. The tumors that consequently develop be-
have like a metastatic brain lesion, and its exact location and
size at each time point are well characterized.
Noninvasive magnetic resonance imaging (MRI) has
demonstrated the capability to perform repeated measure-
ments of tumors implanted intracranially and to measure
changes caused by therapies [25–28]. MRI methods facili-
tate detectability of changes in tumor vascularization, in addi-
tion to their traditional role of measuring tumor volume. There
are few approaches to study antivascular effects by MRI:
permeability to contrast agents [27–31], diffusion-weighted
MRI [32], T1U-weighted method [33], and blood oxygenation
level–dependent (BOLD) contrast [16,25,34,35]. BOLD-MRI
is based on changes in proton signals from tissue that is
adjacent to blood vessels containing paramagnetic deoxy-
hemoglobin [36]. Unlike oxyhemoglobin, which is dia-
magnetic and has minimal effect, deoxyhemoglobin is
paramagnetic and acts as a T2* relaxing agent. Therefore,
the changes in tissue levels of deoxyhemoglobin cause local
magnetic field susceptibility gradients, which can be de-
tected as changes in MRI signal intensities. These changes
correlate with fluctuations in oxygen saturation, blood flow,
and blood volume [37].
The goal of this study was to evaluate the ability of HF
to inhibit tumor growth in a metastatic rat brain tumor model.
By using MRI, we noninvasively monitored the effect of
HF on tumor progression and vascularization. We have se-
lected to use BOLD imaging, a functional MRI technique,
which is susceptible to tumor perfusion, oxygenation, and
vessel reactivity (response to CO2). We have previously
used this method to study tumor angiogenesis and vessel
maturation [16,35,38]; however, so far, it has not been ap-
plied for the evaluation of HF effects on intraparenchymal
brain tumors. In this study, we demonstrate that treatment
with HF reduced tumor growth and angiogenesis of an
intracranially implanted malignant sarcoma in rats and thus
prolonged the survival of treated rats.
Materials and Methods
Materials
HF bromohydrate was obtained from Collgard Biophar-
maceuticals Ltd. (Petach-Tikva, Israel).
Tumor Cell Line
The tumor used for the in vivo experiments is an unse-
lected rat tumor line of a methylcholantrene-induced malig-
nant fibrous histiocytoma as reported previously [23]. The
tumors used for in vivo experiments were maintained in
syngeneic Fischer rats by serial subcutaneous transplanta-
tions. Tumor cell suspension was prepared as previously
described, assayed for viability by the Trypan blue exclusion
test, and resuspended at the appropriate inoculum concen-
tration in RPMI medium. Tumor cells were maintained sub-
cutaneously because in tissue culture, these cells change
their phenotype rapidly. Limited numbers of passages were
used. The same cell suspension was used each time to inject
an equal number of controls and the experiment group of
HF treatment.
Stereotactic Brain Inoculation
Adult female Fischer rats (weighing 180–200 g) were
anesthesized by intraperitoneal injection of 30 mg/kg pento-
barbital; the tumor cell suspension was injected into the right
cerebral hemisphere, using a small animal stereotactic ap-
paratus. With bregma as zero reference point, the stereo-
tactic coordinates were P = 3.5, L = 2, and H = 4 mm, as
previously described [24]. Those coordinates targeted the
tumor cells to the subcortical white matter. The head was
held in a horizontal position and 105 tumor cells suspended
into a 2-ml volume were injected. Tumor cells were injected
slowly for 10 minutes to avoid an acute elevation of intracra-
nial pressure or upward solution leakage through the track
of the injecting needle.
Animal Protocols
Treatment with HF was initiated on day 6 after tumor
implantation, a time when a macroscopic tumor mass had
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already developed [24]. Oral treatment (by oral gavage) was
given daily until animals were sacrificed (for histology anal-
ysis) or left to die (for survival). Animals were observed for
signs of toxicity and weight loss. Rats were housed in cages
at 20jC with a 12-hour light/dark schedule, and free access
to food and water. Animal experiments were approved by
the Animal Care Committee of the Hebrew University Faculty
of Medicine.
Dose evaluation Four groups were evaluated: 1) vehicle;
2) HF, 0.1 mg/kg per day; 3) HF, 0.2 mg/kg per day; and 4)
HF 0.4 mg/kg per day (n = 10 per group). Rats were
sacrificed on day 14. Visible tumor was excised and its three
dimensions were measured for calculation of tumor volume.
HF plasma levels were determined on days 7 and 14. An-
imals were observed for signs of toxicity and weight loss.
Tissue samples of lung, liver, heart, kidney, brain, and spleen
were obtained from each experimental group and evaluated
histologically for signs of toxicity.
Survival Survival was evaluated after randomization to treat-
ment with either vehicle or HF (0.2 and 0.4 mg/kg per day).
Treatment was started on day 6 and continued until death
(n = 12 for each treatment group).
MRI For MRI experiments, only two groups were used:
1) vehicle and 2) HF, 0.4 mg/kg per day. MRI scans were
performed on days 13, 17, and 19 after tumor implantation.
Histology
Anesthesized animals were perfused transcardially with
20 ml of formalin. Brains were removed and immersed in the
same fixative overnight at 4jC. Coronal sections (5 mm) were
cut and stained with hematoxylin and eosin.
Immunohistochemistry
Paraffin-embedded tumor sections were stained for
a-smooth muscle actin (a-SMA) (Sigma Chemical Co.,
St. Louis, MO), in a 1:2500 dilution, to detect vascular
smooth muscle cells and pericytes. Blood vessels were
detected by either Bandeiraea simplicifolia BS-1 Isolectin
(LEC; 1:10 dilution) or antibody to factor VIII (von Willebrand
factor, vWF) (DAKO, Glostrup, Denmark). The vWF antibody
was used in a 1:200 dilution after treating the section with
proteinase K for 10 minutes at 37jC.
MRI Analysis of Tumor Volume, Blood Vessel Functionality,
and Vessel Maturation
MRI experiments were performed on a horizontal 4.7T
Biospec spectrometer (Bruker Medical, Ettlingen, Germany)
using an actively radiofrequancy-decoupled surface coil
(2 cm in diameter) and a birdcage transmission coil [35].
Rats were anesthesized (pentobarbital, intraperitoneally)
and placed in a prone position with the brain located at the
center of the surface coil. Ten rats per group were imaged on
days 13, 17, and 19 after tumor cell inoculation. Intracranial
tumor volume was determined from multislice coronal and
axial fast spin-echo images (repetition time = 2000 milli-
seconds, echo time = 45 milliseconds, slice thickness =
0.85 mm, and field of view = 3.4 cm, using a 256  128
matrix). In brief, the tumor boundary visualized in each slice
was outlined by using image processing software (NIH Im-
age, Bethesda, MD). The number of tumor pixels was con-
verted to an area by multiplication by the factor [(field of
view)2 / (matrix)2]. The total tumor volume was calculated as
the summed area on all slices, multiplied by the slice thick-
ness [39]. Tumor borders were also confirmed with T1-
weighted inversion recovery sequence (repetition time =
2000 milliseconds, echo time = 45 milliseconds, inversion
delay = 250 milliseconds).
Tumor vascular function (VF) and maturation (VD) were
determined from gradient-echo (GE) images acquired during
the inhalation of air, air–CO2 (95% air and 5% CO2), and
oxygen–CO2 (95% oxygen and 5% CO2; carbogen), as
described [35]. Four images were acquired at each gas
mixture (51 sec/image; slice thickness = 0.85 mm; TR =
100 milliseconds; TE = 10 milliseconds; field of view = 3 cm;
256  128 pixels; in-plane resolution = 110 mm; four aver-
ages). Other imaging experimental details were as reported
previously [35,40].
Data Analysis
MRI data were analyzed on a PC computer using IDL
software (Research Systems Inc., Boulder, CO). VF was
derived from images acquired during inhalation of carbogen
and air–CO2 as described previously [35,40], using the
following equation:
VF ¼ bDY ¼ lnðIoxygen=IairÞ=TE CMRI
where Ioxygen and Iair are the mean signal intensity during
inhalation of oxygen and air, respectively; TE is the echo
time; Y is the fraction of oxyhemoglobin; b is the volume
fraction of blood; and CMRI is a factor representing magne-
tic field strength. This parameter measures the capacity of
erythrocyte-mediated oxygen delivery from the lungs to
each pixel in the image [35,40].
Vascular maturation is demonstrated by vasodilation (VD)
in response to change of CO2 levels (from images acquired
during inhalation of air and air–CO2), as described [35,40]:
VD ¼ lnðIairCO2=IairÞ=TE CMRI
Positive VD corresponds to increased signal intensity by
hypercapnia, due to elevated blood oxygenation and/or
increased blood flow [40]. Data are presented in color maps
overlaid on the original baseline image for absolute values
of VD and VF >0.005 [35]. Mean VF and VD values were
calculated from the entire tumor and were divided by the
mean values from a corresponding region with the same size
taken at the homologous contralateral side.
Statistics
Results are expressed as mean ± SD. Differences be-
tween groups were identified by the unpaired Student’s t test.
A P value of less than .05 was considered statistically sig-
nificant. Tumor volume, VF, and VD data were analyzed after
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normalization with logarithmic transformation. Considering
the repeated measurements on the same animals, we used
an appropriate repeatedmeasurement model. Least squares
means for each day (13, 17, and 19) that resulted from the
statistical model were compared in order to find the differ-
ence between the experimental groups. The Bonferroni
method was used to correct for repeated measurements.
The statistical significance of differences in survival time was
analyzed by means of the Wilcoxon ranking test.
Results
Effect of HF on Tumor Growth
The day of inoculation of tumor cells was considered day
0. Oral treatment with HF was initiated on day 6 after tumor
cell implantation, a time when a macroscopic tumor mass
had already developed [24], and repeated daily. On day 14,
tumors were excised (n = 10 per group) and their volume was
calculated bymeasurements of the tumor’s three dimensions
on serial sectioning. Mean brain tumor volume of vehicle-
treated animals (controls) was 49.4 ± 8.4 mm3. Treatment
with HF induced dose-related inhibition of tumor growth:
49% inhibition of tumor growth in dose of 0.1 mg/kg per
day (P = .06), 88% inhibition in dose of 0.2 mg/kg per day
(P = .0005), and 94% inhibition at dose of 0.4 mg/kg per day
(P = .0001). Mean HF plasma levels on day 14 were: 1.32 ±
0.4 ng/ml for dose of 0.1 mg/kg per day, 2.27 ± 0.3 ng/ml
for dose of 0.2 mg/kg, and 4.53 ± 1.02 ng/ml for dose of
0.4 mg/kg. All animals lost weight during the observation
period. Weight loss ranged between 9% and 13% of initial
body weight and did not differ significantly between untreated
tumor-bearing controls and HF-treated animals. No drug-
related toxicity was observed on histologic evaluation of
the internal organs.
In order to study the kinetics of the effect of HF on tumor
growth, we used MRI, which is a noninvasive technique.
Oral treatment with HF (0.4 mg/kg per day) was initiated on
day 6 after tumor cell implantation and repeated daily. MRI
studies were performed on days 13, 17, and 19 after cell
implantation (10 rats per group). Indeed, MRI confirmed the
delay in tumor growth in HF-treated rats in comparison to
control rats (Figure 1; Bonferroni P < .001 for all time points).
In vehicle-treated rats, exponential growth of the tumors
was observed and, on day 19, they covered most of the ipsi-
lateral hemisphere (Figure 1C). A significant inhibition of
tumor growth was detected during the observation period
in HF-treated rats. On day 13, HF-treated tumors were five-
fold smaller than control (Figure 1,B andA, respectively), and
remained threefold smaller on days 17 and 19 (Figure 1, D
andC, respectively). It should be noted that in some cases, in
control-treated rats, the tumor erupted from the skull—
a phenomenon that never occurred in HF-treated rats. Tumor
volume was calculated only from the intracranial mass.
Effect of HF on Rat Survival
As a consequence of growth inhibition, HF treatment
significantly prolonged survival of brain tumor-bearing rats
(Figure 2). The median survival of vehicle-treated animals
was 19 days (range: 15–22 days), while median survival of
the 0.2 mg/kg per day HF group was 21 days (range: 17–26
days) (P = .002) and of the 0.4 mg/kg per day treatment
group was 27 days (range: 21–31) (P = .0001). The increase
in lifespan of the 0.4 mg/kg per day group is 142%. The
difference between the two treatment groups (0.2 and 0.4
mg/kg) is also significant (P = .001).
Effect of HF on Tumor Angiogenesis and Vessel Maturation
The brain is one of the most vascularized organs with a
well-oxygenated blood supply. Malignant brain tumors are
frequently characterized by well-perfused, high-density vas-
cular bed [41]. We evaluated the effect of HF on tumor
vascularization and, indeed, the delay in tumor growth was
accompanied by reduced vascularization in HF-treated
tumors, as determined by VF maps (Figure 3). In HF-treated
rats, tumor vascularization was inhibited by 50% on day 13
and by 37% on day 19 (Figure 3; VF). Using the Bonferroni
method (correction for repeated measurements) revealed
statistically significant influence of HF on tumor vasculariza-
tion (P < .05).
The higher vascularization of control vs. HF-treated
tumors was confirmed by immunostaining of histologic sec-
tions with both lectin and anti– factor VIII antibody (Figure 4,
A–D). Microvessel counts revealed that on day 13, the mean
count per  40 microscopic field was 16.0 ± 3.5 for controls
and 7.5 ± 1.8 vessels, for the HF group (P = .00001). On day
19, there were less vessels in each field, 9.5±2 vessels in
controls vs. 6.0 ± 2.8 vessels in HF-treated tumors (P = .03,
two tumors per group, 10 fields per tumor). In addition, on
day 19, control tumors contained larger vessels (Figure 4C,
insert) as compared with the HF-treated ones.
Using MRI, we were also able to study the effects of HF
on vessel maturation. In control tumors, vessel maturation
progressed from the tumor margins inwards and the percent
of mature vessels increased from days 14 to 19 by approx-
imately 50%. HF treatment significantly inhibited vessel
maturation (Bonferroni P = .03) (Figure 3; VD). These results
were confirmed by staining tissue sections with a-SMA anti-
body (Figure 4, E and F ). There were few blood vessels,
which stained positively with a-SMA antibody within control
tumors (Figure 4E, red arrows). At the same time, in the
HF-treated tumors, we could find no mature vessels within
the tumor mass. However, numerous a-SMA positive
mature vessels were observed in the vicinity of the HF-
treated tumor mass, which were covered with few layers
of tumor cells (cooption) (Figure 4F, red arrows).
Effect of HF on Tumor Morphology
The tumors used for our studies usually grew as relatively
well-circumscribed intraparenchymal masses in Fischer rats
[24] (Figures 1 and 4). InHF-treated rats, we observed amod-
erate 2.4-fold increase in the number of satellite tumors that
were clustered around—but distinct from—the primary lesion
(Figure 4, B and F, black arrows). These satellites were clus-
tered around the main mass and usually contained discern-
ible vessel cores (Figure 4B). On some sections, it could be
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demonstrated that the satellites represented cross-section-
ing of vessels that were surrounded over a long distance by
a perivascular coat of tumor cells (Figure 4F, arrow).
Discussion
Although conventional chemotherapeutic agents have a
direct cytotoxic effect on tumor cells, they induce a high
incidence of drug resistance as well as serious systemic
adverse effects. In contrast, recent antiangiogenic substan-
ces, such as small molecule inhibitors, are less likely to
develop drug resistance and serious side effects because
they target only activated ECs on a molecular basis, instead
of unselected cell population. Although the effect is tempo-
rary and cytostatic, these new agents inhibit angiogenesis
Figure 1. HF inhibits tumor growth in a metastatic rat brain tumor model. Fischer rats were inoculated in the right cerebral hemisphere with 10 5 malignant fibrous
histiocytoma. Oral treatment with HF (0.4 mg/kg per day) or control vehicle was initiated on day 6 after tumor implantation, and treatment was repeated daily. Tumor
growth kinetics was followed from consecutive fast spin-echo images (repetition time = 2000 milliseconds, echo time = 45 milliseconds, slice thickness = 0.85 mm,
and field of view = 3.4 cm) of the tumor. Rats were scanned on days 13, 17, and 19 after tumor implantation. Representative axial T2-weighted SE images of a control-
treated rat (A and C) versus HF (0.4 mg/kg per day)– treated rat (B and D). Images were acquired on days 13 (A and B) and 19 (C and D) after cell inoculation
(arrowhead = tumor; bar = 1 cm). (E) Mean tumor volume (mm3) of HF-treated (x) versus control (n), determined from SE images as a function of time after cell
inoculation (n = 10 rats per group; *P < .001 for all time points).
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and lead to small avascular tumors, which are maintained in
a dormant state.
Brain tumors are highly angiogenic and dependent on
neovascularization for their continued growth and invasion.
Antiangiogenesis is thus a potentially important therapeutic
strategy for these malignancies. In this study, we demon-
strate that HF, an inhibitor of angiogenesis, is effective as a
single therapeutic modality in an animal model with a meta-
static brain tumor. We show that growth inhibition is dose-
dependent and that tumor volumes in HF-treated rats were
reduced by 88% to 94 % on day 14 after cell implantation in
comparison to controls. This inhibitory effect could be dem-
onstrated even when treatment was delayed and given at a
time when a macroscopic tumor mass had already devel-
oped (day 6 after cell implantation) [24]. Concurrently, HF
significantly prolonged rat survival. Our MRI analysis indi-
cates that the inhibitory effect of HF on tumor growth was
associated with a significant reduction of tumor angiogenesis
and vessel maturation.
Ideally, treating an established human tumor with anti-
angiogenic therapy requires not only the inhibition of
further angiogenesis, but also loss of existing tumor ves-
sels to reduce the existing tumor mass. To recognize such
an effect, features that distinguish a preformed tumor
vasculature from host vessels are sought, and one such
feature is the state of vessel maturation. It was shown
previously that human brain tumors contain a significant
fraction of immature vessels. In tumor specimens of glio-
blastoma multiforme, less than one quarter of tumor ves-
sels, larger than capillaries, was associated with a-SMA–
positive cells [42]. The presence of a large fraction of
immature vessels in these tumors was in sharp contrast
to the normal brain, where the majority of vessels were
covered by a-SMA–positive cells [42]. From both MRI and
histology results, it seems that HF reduces both the
process of vessel maturation and its well-demonstrated
antiangiogenic effect.
With the expeditious development of new antiangio-
genic therapies, there is a growing need for noninvasive
methods that will monitor the response of tumor vasculature
to these biologic manipulations. Optimal treatment monitor-
ing should rely on biologic endpoints, which indicate that
angiogenesis is actually inhibited. The current study demon-
strates that MRI could serve this purpose. We clearly show
that MRI is a potential tool for in vivo monitoring not only
of tumor volume, but also of tumor vascularization and
the status of its vascular maturation. The use of BOLD
contrast MRI for monitoring the effect of treatment with
antiangiogenic drugs in animal tumor models was previ-
ously described [16,25,31,43]. Nevertheless, we demon-
strate here that, even in the brain, a well-oxygenated
organ, MRI provides a powerful noninvasive tool for moni-
toring treatment effects while exploiting changes in gas
breathed.
Previous studies showed that the effects of HF on the
growth and vascularization of subcutaneous C6 glioma were
more dramatic than our current experience [16]. Indeed, the
subcutaneous model is very useful to study basic principles
of angiogenesis and antiangiogenesis, but it is unclear
whether extrapolation of these results to the intracerebral
localization is valid. Subcutaneous tumors characteristically
grow in an encapsulated fashion while brain tumors tend to
grow in a more infiltrative manner [44]. Thus, it is important to
study the therapeutic effects in a more suitable environment
that mimic the actual milieu for tumor growth. Our study
indicates that HF is effective even when the tumor involves
the brain parenchyma and it produces inhibitory effects on
tumor growth similar to the previous findings in subcutane-
ous models.
Vessel cooption is thought to precede angiogenesis in the
progression of astrocytomas and low-grade brain tumors
[45]. In this work, tumor cells are mesenchymal in origin
and their behavior is different from that of low-grade brain
tumor. In this model, tumor progression is very rapid (the rats
died 19 days postinjection) and is highly angiogenic. Only
after HF treatment did we observe the appearance of vessel
cooption, similar to what is known for untreated low-grade
brain tumors. It seems that angiogenesis inhibition promotes
tumor growth along pre-existing vessels, independently of
neovascularization.
The hypothesis of a vascular dependency of tumors is
very attractive, but it raises some unsolved issues related to
Figure 2. Effect of HF on rat survival. Fischer rats were inoculated in the right cerebral hemisphere with 10 5 malignant fibrous histiocytoma. Oral treatment with HF
[0.2 mg/kg per day (n); 0.4 mg/kg per day (E)] or control vehicle (.) was initiated on day 6 after tumor implantation, and treatment was repeated daily until animal
death. Survival of the rats was monitored daily (n = 12 rats per group).
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antiangiogenic treatment. For example, malignant glial
tumors frequently show an infiltrative growth pattern [1].
The infiltrative trails include dissemination of tumor cells
along existing tissue spaces and migration along blood
vessels (vessel cooption). These tumor cells are likely to
receive an adequate blood supply by the normal brain
vasculature, thereby reducing the necessity to induce new
vascular supply [1]. From these observations, it can be
predicted that although the growth of the tumor bulk might
be angiogenic-dependent, antiangiogenic therapy alone
would be unlikely to succeed in killing all tumor cells.
Former experiments showed that gliomas could coopt
pre-existent cerebral vessels to provide their blood supply,
before they induce neovascularization [21]. In our work, we
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Figure 3. Effect of HF on vascular function (VF) and maturation (VD) in metastatic brain tumors. Representative axial gradient echo (GE) images of control (A) and
HF-treated (D) rats acquired on day 17 after tumor implantation. Functionality and maturation of the vasculature were derived from GE images acquired during
inhalation of air, air –CO2, and carbogen. Color-coded VF and VD maps were derived and overlaid [|VF| > .005; |VD| > .005; see color scale in (H)] on original
images. Note the higher vessel density at the tumor periphery and the reduced vascular function (VF) and maturation (VD) in HF-treated tumors (E and F) versus
controls (B and C) (bar = 1 cm). (G) Mean tumor VF and VD. The mean ± SD values of VF and VD were calculated from the region of interest containing the whole
tumor and normalized as fold over values in normal brain, applying six rats per group and two to three slices per tumor. Bonferroni method (correction for repeated
measurements) revealed statistically significant influences of HF on tumor vascularization (VF) and maturation (VD), P < 0.05.
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demonstrate that HF, an antiangiogenic compound, in-
creased satellite tumors and vessel cooption in our meta-
static brain tumor model. There are two previous publications
[46,47] that have shown that anti-VEGF treatment increased
invasiveness and cooption of host vessels in models of
glioblastoma. This suggests that in the therapeutic situation,
where angiogenesis is inhibited, a blockade of neovascula-
rization favors vessel cooption. Moreover, this seems to be
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Figure 4. Effect of HF on vessel density and maturation in metastatic brain tumors. Fischer rats were inoculated with malignant fibrous histiocytoma. Oral treatment
with HF (0.4 mg/kg per day) or control vehicle was initiated on day 6 after tumor implantation, and treatment was repeated daily. On days 14 and 19, tumor samples
were collected for histologic examination. Representative slides of control tumors (A, C, E) and HF-treated tumors (B, D, F) obtained on day 14 are presented.
(A–D) Anti – factor VIII (vWF) immunostaining of control (A and C) and HF-treated (B and D) rats. Black arrows indicate vessel cooption phenomena, and
arrowheads mark the well-defined borders of control tumor. (E and F) Anti-SMA immunostaining of control (E) and HF-treated (F) rats. Red arrows mark
blood vessels stained positively with A-SMA antibody. Magnification is indicated on top of each figure.
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independent of the antiangiogenic mechanism of action
(anti-VEGF versus HF inhibitory affect on collagen I synthe-
sis). In addition, this indulgence of invasiveness seems to
occur across all tumor types even in a metastatic tumor that
usually tends to grow as a well-defined mass. We should
emphasize that with anti-VEGF antibody, there was a 23-fold
increase in satellite tumor mass [46], and with DC101, an
antibody against VEGF receptor-2, there was a fivefold
increase in the number of satellites [47], whereas with HF,
we observed only a 2.4-fold increase. Thus, the antitumor
effect of HF, in addition to its antiangiogenic effect, seems to
moderate the cooption effect.
In summary, we have shown that systemic treatment with
HF inhibits the growth and vascularization of metastatic brain
tumors and concurrently prolonged the survival of the ani-
mals, yet moderately increased tumor cooption and inva-
siveness along host vessels. Apparently, it seems that for
better anticancer effect, there is a need to combine additional
therapeutic modalities such as concomitant use of chemo-
therapy or other newly evolving biologic therapies. However,
in the CNS, such combinations are particularly challenging
due to the limitations posed by the blood–brain barrier. The
possibility of combining HF with radiation therapy needs
further investigation because radiosensitivity depends on
oxygenation. Further studies are needed to evaluate appro-
priate combinations, dosing, and schedule of such therapeu-
tic approaches in both primary and metastatic brain tumors.
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